90
Views
18
CrossRef citations to date
0
Altmetric
Drug Evaluation

Imatinib mesilate for the treatment of gastrointestinal stromal tumour

, , , , , , , , , , , & show all
Pages 1211-1222 | Published online: 21 Apr 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Samia Arifi. (2022) Personalised pharmacotherapy options for soft tissue sarcomas. Expert Review of Precision Medicine and Drug Development 7:1, pages 17-28.
Read now
Rashmi Chugh & Laurence H Baker. (2009) Pharmacotherapy of sarcoma. Expert Opinion on Pharmacotherapy 10:12, pages 1953-1963.
Read now

Articles from other publishers (16)

Linda C. Harlan, Jana Eisenstein, Maria C. Russell, Jennifer L. Stevens & Kenneth Cardona. (2015) Gastrointestinal stromal tumors: Treatment patterns of a population-based sample. Journal of Surgical Oncology 111:6, pages 702-707.
Crossref
Junaid Ansari, Reinhold Munker & Amol Takalkar. (2015) Current role of FDG-PET in Bone and Soft tissue tumors. Journal of Bone and Soft Tissue Tumors 1:1, pages 29-36.
Crossref
Michael Tagen & Clinton F. Stewart. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics 625 659 .
Richa Pandey & Rajan Kochar. (2012) Management of Gastrointestinal Stromal Tumors: Looking Beyond the Knife. An Update on the Role of Adjuvant and Neoadjuvant Imatinib Therapy. Journal of Gastrointestinal Cancer 43:4, pages 547-552.
Crossref
Aurore Blesius, Philippe A Cassier, François Bertucci, Jerome Fayette, Isabelle Ray-Coquard, Binh Bui, Antoine Adenis, Maria Rios, Didier Cupissol, David Pérol, Jean-Yves Blay & Axel Le Cesne. (2011) Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 11:1.
Crossref
Y. Baran, S. Zencir, Z. Cakir, E. Ozturk & Z. Topcu. (2011) Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition. Journal of Clinical Pharmacy and Therapeutics 36:6, pages 673-679.
Crossref
Marcus Schlemmer, Steven P. Sourbron, Nicole Schinwald, Konstantin Nikolaou, Christoph R. Becker, Maximilian F. Reiser & Frank Berger. (2011) Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. European Journal of Radiology 77:2, pages 312-318.
Crossref
T Kanazawa, M Nokubi, K Takizawa, S Matsuzawa, A Shinnabe, H Mineta & Y Iino. (2010) KIT and platelet-derived growth factor receptor α gene expression in laryngeal small cell carcinoma . The Journal of Laryngology & Otology 124:12, pages 1340-1343.
Crossref
David Reynoso & Jonathan C Trent. (2010) Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. Current Opinion in Oncology 22:4, pages 330-335.
Crossref
Jerry Call, Norman J. Scherzer, P. David Josephy & Christopher Walentas. (2009) Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study. Journal of Gastrointestinal Cancer 41:1, pages 60-70.
Crossref
Houcine Bougherara, Frédéric Subra, Ronan Crépin, Patrick Tauc, Christian Auclair & Marie-Alix Poul. (2009) The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment. Molecular Cancer Research 7:9, pages 1525-1533.
Crossref
. (2009) Current World Literature. Current Opinion in Oncology 21:4, pages 386-392.
Crossref
Ronan J. Kelly, Bertrand Billemont & Olivier Rixe. (2009) Renal toxicity of targeted therapies. Targeted Oncology 4:2, pages 121-133.
Crossref
Charanjit Kaur & Caroline Finlayson. (2009) Anal spindle cell lesion. Diagnostic Histopathology 15:1, pages 51-54.
Crossref
Cindy H. Chau, Olivier Rixe, Howard McLeod & William D. Figg. (2008) Validation of Analytic Methods for Biomarkers Used in Drug Development. Clinical Cancer Research 14:19, pages 5967-5976.
Crossref
A. Martinschek, C.G. Ruf, C. Sparwasser & H.U. Schmelz. (2008) Der Stellenwert der Targeted-Therapie beim HodentumorValue of targeted treatment for testicular cancer. Der Urologe 47:10, pages 1328-1333.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.